📚 Part of the GLPI-103 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.
This is a mock / simulation document, made for a portfolio and for learning. The drug (GLPI-103), the sponsor, the people, and the data are all fictional. It is not a real regulatory submission and has no clinical, legal, or regulatory standing. What is real is the shape of the thing — the document structure, the standards it follows, and the analysis methods; the content inside is illustrative.
What it is. The pediatric development plan — the US Pediatric Study Plan (PSP) and the EU Paediatric Investigation Plan (PIP).
Why it exists. Both the FDA and EMA require sponsors to plan (or justify deferral/waiver of) studies in children early in development. The plan states what pediatric studies will be done, or why they are not needed, for GLPI-103.
How it is produced here. This is a region-specific administrative document, assembled to the local filing and labeling conventions. Its operational and label content is written to stay consistent with the (simulated) clinical data.
Format & governing standard. FDA PREA/PSP; EU Paediatric Regulation (PIP)
| Field | Value |
|---|---|
| Document ID | PED-001 |
| Version | 1.0 |
| Standard | FDA PREA/PSP; EU Paediatric Regulation (PIP) |
| Confidentiality | Confidential — portfolio use |
Combined summary of the US Pediatric Study Plan (PSP) and EU Paediatric Investigation Plan (PIP) required for the marketing application.
[MOCK].
No comments yet. Be the first to say something!
| Version | Date | Author | Summary |
|---|
| 1.0 | 2026-06-29 | Regulatory | Initial pediatric plan |
Type 2 diabetes mellitus occurs in adolescents; a pediatric development plan is required (or a waiver/deferral justified) for the new active substance.
PSP agreed with FDA (PREA); PIP agreed with the EMA Paediatric Committee (PDCO), including key binding measures and timelines. Updates submitted as the program matures.